IL2 and neoplasm: A promising radiosensitiser is L-19-IL2, which is an immunocytokine that has been shown in preclinical models to deliver IL-2 to tumour cells via the selective L-19 dependent binding of the extra domain B of fibronectin located on tumour vasculature endothelium [69].